Chuanguan News reporter Li Huan
The reporter learned from the West China Second Hospital of Sichuan University that the “International Clinical Guidelines for the Treatment of Vasculitis” led by Zeng Linan, an associate professor of the hospital, as the “Chairman of Guideline Methodology”, was recently published in Published by the British Medical Journal (BMJ), one of the world’s four top comprehensive medical journals, the guidelines are of great significance to guide the world in the field of vasculitis treatment.
According to Zeng Linan, as an important means of transforming clinical research evidence into clinical practice, the release of this guideline is a landmark achievement of the West China Second Hospital of Sichuan University in the field of clinical research work, reflecting the hospital’s The important international contribution and academic influence in the field of clinical guideline formulation demonstrates the academic status and discourse power of Chinese scholars in the field of international clinical practice standard formulation.
It is known that vasculitis is an autoimmune disease characterized by inflammation and damage to small blood vessels, with an incidence of about 1 in 50,000 adults. Although the incidence of the disease is not high, patients are often accompanied by vascular damage to the kidneys and lungs, severe pain in muscles and joints, blood in the stool, abdominal pain and other complications, which seriously affect the quality of life of patients. Patients are usually diagnosed after seeking medical treatment due to respiratory tract, digestive tract or other symptoms. This examination is not involved in routine physical examinations, so it is difficult to detect patients. Can plasma exchange therapy be added to routine immunosuppressive therapy to reduce patient mortality? The incidence of end-stage renal disease has been controversial. In addition, the glucocorticoid dose escalation regimen adopted in immunotherapy in different countries and regions also varies greatly.
What makes it difficult for doctors all over the world is that although the diagnosis and treatment of vasculitis in many countries around the world has improved, the mortality rate of patients with vasculitis has decreased, but due to disease complications (such as , renal failure or pulmonary hemorrhage) and complications due to immunosuppressive therapy (eg, serious infection or cancer), the mortality rate of patients with vasculitis is still 2.6 times higher than that of the general population. In such cases, establishing a “gold standard” for the treatment of vasculitis is crucial.
This guideline is based on the best current clinical research evidence and patient preferences. Recommendations are formulated for difficult problems in the field of vasculitis treatment. According to the risk of end-stage renal disease in patients with vasculitis, the applicable population of plasma exchange therapy is clearly recommended for the first time, and the relevant treatment plan is formulated. The release of the guideline will have a significant impact on the clinical treatment plan of vasculitis.